Bankruptcy Opportunity With Akorn’s Chapter 7 bankruptcy in early 2023 and asset liquidation activity in 2023, there may be opportunities for strategic purchasers or partners to acquire remaining portfolios, manufacturing capacity, or niche ophthalmic and injectable product lines through liquidators or courts.

Ophthalmic Footprint Akorn has a strong focus on ophthalmics, including branded and generic products across eye drops and related delivery forms, suggesting potential to target ophthalmology distributors, clinics, or specialty pharmacies needing aligned supply or API/formulation expertise.

Diversified Formulations The company develops across multiple dosage forms (ophthalmics, injectables, oral liquids, otics, topicals, inhalants, nasal sprays), indicating opportunities to partner on multi-formulation programs, contract manufacturing, or co-development with firms seeking diverse dosage form capabilities.

R&D and Capacity With R&D facilities in Vernon Hills and Cranbury and manufacturing plants in Illinois, New Jersey, New York, and Switzerland, there is a potential to offer collaboration on product development, regulatory support, or toll manufacturing for niche or orphan ophthalmic and injectable products.

Cost-Effective Supply Despite past turmoil, Akorn positions itself on quality, availability, and affordability. Potential sales angles include price-competitive contract manufacturing, inventory liquidation services, or rescue supply arrangements for brands seeking reliable ophthalmic or injectable outputs.